Literature DB >> 24854433

Telomerase as a tumor marker in diagnosis of prostatic intraepithelial neoplasia and prostate cancer.

P V Glybochko1, E G Zezerov, A I Glukhov, Yu G Alyaev, S E Severin, K A Polyakovsky, V A Varshavsky, E S Severin, A Z Vinarov.   

Abstract

BACKGROUND: Early diagnosis of prostate cancer (CaP) can be addressed by studying prostatic intraepithelial neoplasia (PIN) as precancer (high-grade PIN or HGPIN). This article attempts to analyze the diagnostic role of telomerase as an early marker of carcinogenesis.
METHODS: Complex urological patient evaluation and assessment of telomerase activity.
RESULTS: Out of 92 patients 44% were diagnosed with CaP, 49% with low-grade PIN (LGPIN) in association with benign prostatic hyperplasia (BPH), and 7% with HGPIN in association with BPH. Active telomerase (AT) in prostate biopsy specimens was detected in 98% of patients with CaP, in 33% of patients with HGPIN, and in 20% of patients with LGPIN. In the event of simultaneous detection of AT and PIN in initial prostate biopsy specimens, further monitoring for 0.5-4.0 years revealed CaP development in 50-56% of cases. Further follow-up of patients with PIN and absent telomerase activity in initial biopsy specimens did not demonstrate the development of CaP. The PSA level was significantly higher in patients with active telomerase in the prostate tissue than in telomerase negative patients.
CONCLUSIONS: Telomerase activity in the prostate tissue increases the risk of CaP development in patients with PIN. Detection of telomerase activity in prostate biopsy specimens from patients with PIN enables selection of a group of patients with high risk of CaP development and reduction of the number of prostate biopsies performed in other patients.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  dynamic process of prostate carcinogenesis; precancer; prostate cancer; prostate-specific antigen; prostatic intraepithelial neoplasia; telomerase

Mesh:

Substances:

Year:  2014        PMID: 24854433     DOI: 10.1002/pros.22823

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer.

Authors:  Benjamin A Rybicki; Sudha M Sadasivan; Yalei Chen; Ian Loveless; Nilesh S Gupta; Dhananjay A Chitale; Sean R Williamson; Andrew G Rundle; Deliang L Tang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-05-04       Impact factor: 4.090

2.  Shorter telomeres and high telomerase activity correlate with a highly aggressive phenotype in breast cancer cell lines.

Authors:  Hugo A Ceja-Rangel; Patricia Sánchez-Suárez; Emilio Castellanos-Juárez; Rubicelia Peñaroja-Flores; Diego J Arenas-Aranda; Patricio Gariglio; Luis Benítez-Bribiesca
Journal:  Tumour Biol       Date:  2016-04-12

Review 3.  Telomerase Inhibitors from Natural Products and Their Anticancer Potential.

Authors:  Kumar Ganesan; Baojun Xu
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923

4.  Construction of a novel vector expressing Survivin-shRNA and fusion suicide gene yCDglyTK and its application in inhibiting proliferation and migration of colon cancer cells.

Authors:  Ling Ye; Yuan Yang; Xin-Yu Ma; Dan Li; Mei-Li Xu; Pan Tan; Li-Min Long; Hai-Qin Wang; Ting Liu; Yong-Hong Guo
Journal:  Exp Ther Med       Date:  2017-09-20       Impact factor: 2.447

Review 5.  Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.

Authors:  Ricardo Leão; Joana Dias Apolónio; Donghyun Lee; Arnaldo Figueiredo; Uri Tabori; Pedro Castelo-Branco
Journal:  J Biomed Sci       Date:  2018-03-12       Impact factor: 8.410

6.  Camptothecin shows better promise than Curcumin in the inhibition of the Human Telomerase: A computational study.

Authors:  Adekunle Babajide Rowaiye; Yoroshi Joana Teca Mendes; Samson Ayodeji Olofinsae; John Breakthrough Oche; Oluwakemi Hannah Oladipo; Okiemute Ajiroghene Okpalefe; Joyce Oloaigbe Ogidigo
Journal:  Heliyon       Date:  2021-08-10

7.  Suppressor of Ty homolog-5, a novel tumor-specific human telomerase reverse transcriptase promoter-binding protein and activator in colon cancer cells.

Authors:  Rui Chen; Jing Zhu; Yong Dong; Chao He; Xiaotong Hu
Journal:  Oncotarget       Date:  2015-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.